EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSDLEG00000013362
Gene Symbol: MAP3K10
3 Cross references
186 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSDLEG00000003523
Gene Symbol: MAP3K11
3 Cross references
184 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSDLEG00000003715
Gene Symbol: MAP3K12
3 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSDLEG00000008528
Gene Symbol: MAP3K13
3 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSDLEG00000018645
Gene Symbol: MAP3K5
3 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSDLEG00000005174
Gene Symbol: MAP3K8
3 Cross references
199 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSDLEG00000010862
Gene Symbol: MAP3K9
3 Cross references
195 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSDLEG00000019834
Gene Symbol: MAOA
1 Cross references
147 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSDLEG00000019843
Gene Symbol: MAOB
1 Cross references
333 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSDLEG00000010650
Gene Symbol: MGLL
1 Cross references
209 Possible Orthologues:

Myeloperoxidase

Ensembl ID : ENSDLEG00000006704
Gene Symbol: MPO
3 Cross references
182 Possible Orthologues:

Natriuretic Peptide Receptor 1

Ensembl ID : ENSDLEG00000010307
Gene Symbol: NPR1
3 Cross references
186 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).